JP2006528242A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528242A5
JP2006528242A5 JP2006532854A JP2006532854A JP2006528242A5 JP 2006528242 A5 JP2006528242 A5 JP 2006528242A5 JP 2006532854 A JP2006532854 A JP 2006532854A JP 2006532854 A JP2006532854 A JP 2006532854A JP 2006528242 A5 JP2006528242 A5 JP 2006528242A5
Authority
JP
Japan
Prior art keywords
compound
hydroxy
composition
compound according
palladium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006532854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528242A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/014302 external-priority patent/WO2004101525A1/en
Publication of JP2006528242A publication Critical patent/JP2006528242A/ja
Publication of JP2006528242A5 publication Critical patent/JP2006528242A5/ja
Withdrawn legal-status Critical Current

Links

JP2006532854A 2003-05-08 2004-05-07 アリールアニリンβ2アドレナリン作動性レセプターアゴニストの結晶性形態 Withdrawn JP2006528242A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46881003P 2003-05-08 2003-05-08
PCT/US2004/014302 WO2004101525A1 (en) 2003-05-08 2004-05-07 Crystalline form of aryl aniline beta-2 adrenergic receptor agonist

Publications (2)

Publication Number Publication Date
JP2006528242A JP2006528242A (ja) 2006-12-14
JP2006528242A5 true JP2006528242A5 (cg-RX-API-DMAC7.html) 2007-06-14

Family

ID=33452233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006532854A Withdrawn JP2006528242A (ja) 2003-05-08 2004-05-07 アリールアニリンβ2アドレナリン作動性レセプターアゴニストの結晶性形態

Country Status (6)

Country Link
US (1) US7060712B2 (cg-RX-API-DMAC7.html)
EP (1) EP1622875B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006528242A (cg-RX-API-DMAC7.html)
AT (1) ATE450511T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004024383D1 (cg-RX-API-DMAC7.html)
WO (1) WO2004101525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
AR040962A1 (es) * 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
EP1786762A2 (en) * 2004-09-10 2007-05-23 Theravance, Inc. Amidine substituted aryl aniline compounds
GB0426164D0 (en) * 2004-11-29 2004-12-29 Novartis Ag Organic compounds
EA200701260A1 (ru) * 2005-01-11 2008-02-28 Глаксо Груп Лимитед Циннаматные соли бета-2 адренергического агониста
GB0512246D0 (en) * 2005-06-15 2005-07-27 Glaxo Group Ltd Novel pharmaceutical
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
GB0613154D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
TW200840578A (en) * 2006-12-15 2008-10-16 Procter & Gamble Compositions of azimilide dihydrochloride
US20120178762A1 (en) 2006-12-15 2012-07-12 Warner Chilcott Company, Llc Compositions of azimilide dihydrochloride
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
KR20180085068A (ko) 2011-06-10 2018-07-25 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
PL3517541T3 (pl) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Postać polimorficzna propionianu flutykazonu
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
GB9713819D0 (en) 1997-06-30 1997-09-03 Glaxo Group Ltd Method of reducing the systemic effects of compounds
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ グループ リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate

Similar Documents

Publication Publication Date Title
JP2005533860A5 (cg-RX-API-DMAC7.html)
JP5253696B2 (ja) 抗腫瘍作用を有するインドリル−3−グリオキシル酸誘導体
JP2008518904A5 (cg-RX-API-DMAC7.html)
JP2008519814A5 (cg-RX-API-DMAC7.html)
HRP20130192T1 (hr) Kristalni oblik bifenilnog spoja
EP1262475A4 (en) INDOIND DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
WO2005058835A2 (en) Methods of preparing aripiprazole crystalline forms
HRP20100035T1 (hr) Kristalni oblici bifenilnog spoja
JP2007518738A5 (cg-RX-API-DMAC7.html)
JP2008512470A5 (cg-RX-API-DMAC7.html)
JP2010529986A5 (cg-RX-API-DMAC7.html)
JP2012533550A5 (cg-RX-API-DMAC7.html)
JP2013541592A5 (cg-RX-API-DMAC7.html)
JP2013538857A5 (cg-RX-API-DMAC7.html)
JP2013518040A5 (cg-RX-API-DMAC7.html)
JP2018529657A5 (cg-RX-API-DMAC7.html)
WO2020208592A1 (en) Process for preparation of erdafitinib, its purification and amorphous solid dispersion
JP2008535848A5 (cg-RX-API-DMAC7.html)
CN102471273B (zh) 2-[[[2-[(羟基乙酰基)氨基]-4-吡啶基]甲基]硫代]-n-[4-(三氟甲氧基)苯基]-3-吡啶甲酰胺苯磺酸盐、其晶体、其多晶型物以及用于制备其的方法
JP2007520546A (ja) モンテルカストナトリウムの安定な非晶質性形態
JP2022523196A5 (cg-RX-API-DMAC7.html)
JP2018510189A5 (cg-RX-API-DMAC7.html)
JP2018508549A5 (cg-RX-API-DMAC7.html)
CN102686588A (zh) {4,6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}氨基甲酸甲酯的新溶剂合物
JP2007530652A (ja) 化学物質、調製方法、及び、新規結晶形態